CNDA investigating Changsheng Bio-tech's rabies vaccine production

Investigation and treatment of China’s State Council's investigation team on Changchun Changsheng Bio-tech's illegal production of rabies vaccine cases is under way, and the China National Drug Administration (CNDA) is maintaining communication with the World Health Organization’s (WHO) representative office in China.

Changchun Changsheng Bio-tech began recalling the related export vaccines on July 16, and the CNDA will continue to supervise the recall, the agency said.

Changsheng Bio-tech reportedly used expired materials in some vaccine batches and falsified data, including batch numbers and production dates. Changsheng, which produces about 23% of China’s rabies vaccines, was fined 3.4 million renminbi ($502,200) and ordered to halt all rabies vaccine production and recall flawed doses.